Cutler Group LP Bristol Myers Squibb CO Call Options Transaction History

Cutler Group LP

$307 Million
Q1 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$47.98 - $54.4 $6.06 Million - $6.87 Million	-126,300 Reduced 99.92%	100 $0
Q4 2023 Jan 18, 2024	BUY	$48.48 - $57.85 $2.59 Million - $3.09 Million	53,400 Added 73.15%	126,400 $54,000
Q3 2023 Nov 07, 2023	BUY	$57.89 - $64.73 $4.12 Million - $4.6 Million	71,100 Added 3742.11%	73,000 $22,000
Q2 2023 Jul 18, 2023	SELL	$63.71 - $70.74 $165,646 - $183,924	-2,600 Reduced 57.78%	1,900 $2,000
Q1 2023 May 01, 2023	SELL	$65.71 - $74.53 $6.75 Million - $7.66 Million	-102,800 Reduced 95.81%	4,500 $4,000
Q4 2022 Feb 07, 2023	BUY	$68.48 - $81.09 $458,816 - $543,303	6,700 Added 6.66%	107,300 $791,000
Q3 2022 Oct 25, 2022	SELL	$0.13 - $76.84 $2,444 - $1.44 Million	-18,800 Reduced 15.75%	100,600 $840,000
Q2 2022 Aug 04, 2022	SELL	$72.62 - $79.98 $21 Million - $23.2 Million	-289,500 Reduced 70.8%	119,400 $1.46 Million
Q1 2022 Apr 14, 2022	BUY	$61.48 - $73.72 $23.3 Million - $28 Million	379,200 Added 1276.77%	408,900 $796,000
Q4 2021 Jan 18, 2022	SELL	$53.63 - $62.52 $2.36 Million - $2.75 Million	-44,000 Reduced 59.7%	29,700 $16,000
Q3 2021 Oct 26, 2021	SELL	$59.17 - $69.31 $940,803 - $1.1 Million	-15,900 Reduced 17.75%	73,700 $27,000
Q2 2021 Jul 19, 2021	BUY	$61.91 - $67.42 $2.8 Million - $3.05 Million	45,300 Added 102.26%	89,600 $77,000
Q1 2021 Apr 26, 2021	SELL	$59.34 - $66.74 $5.31 Million - $5.97 Million	-89,500 Reduced 66.89%	44,300 $57,000
Q4 2020 Jan 21, 2021	BUY	$57.74 - $65.43 $1.25 Million - $1.41 Million	21,600 Added 19.25%	133,800 $88,000
Q3 2020 Oct 27, 2020	SELL	$57.43 - $63.64 $4.83 Million - $5.35 Million	-84,100 Reduced 42.84%	112,200 $333,000
Q2 2020 Jul 22, 2020	SELL	$54.82 - $64.09 $8.85 Million - $10.3 Million	-161,400 Reduced 45.12%	196,300 $1.17 Million
Q1 2020 May 07, 2020	SELL	$46.4 - $67.43 $969,760 - $1.41 Million	-20,900 Reduced 5.52%	357,700 $403,000
Q4 2019 Feb 06, 2020	BUY	$49.21 - $64.19 $8.96 Million - $11.7 Million	182,000 Added 92.57%	378,600 $569,000
Q3 2019 Oct 28, 2019	BUY	$42.77 - $50.71 $354,991 - $420,893	8,300 Added 4.41%	196,600 $496,000
Q2 2019 Aug 09, 2019	SELL	$44.62 - $49.34 $14.4 Million - $16 Million	-323,800 Reduced 63.23%	188,300 $175,000
Q1 2019 May 10, 2019	BUY	$45.12 - $53.8 $19.5 Million - $23.3 Million	432,200 Added 540.93%	512,100 $156,000
Q4 2018 Feb 05, 2019	SELL	$48.76 - $63.23 $2.23 Million - $2.89 Million	-45,700 Reduced 36.39%	79,900 $23,000
Q3 2018 Nov 07, 2018	BUY	$55.19 - $62.25 $6.3 Million - $7.1 Million	114,100 Added 992.17%	125,600 $876,000
Q2 2018 Aug 10, 2018	SELL	$50.53 - $62.98 $3.53 Million - $4.4 Million	-69,900 Reduced 85.87%	11,500 $24,000
Q1 2018 May 11, 2018	BUY	$59.92 - $68.98 $3.87 Million - $4.46 Million	64,600 Added 384.52%	81,400 $159,000
Q4 2017 Jan 17, 2018	SELL	$59.94 - $65.35 $1.37 Million - $1.49 Million	-22,800 Reduced 57.58%	16,800 $34,000
Q3 2017 Oct 17, 2017	BUY	$55.23 - $63.74 $2.19 Million - $2.52 Million	39,600	39,600 $173,000

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$11.1 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.34 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.47 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.59 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.59 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account